Navigation Links
New lymphoma therapies targets diverse and difficult cancer
Date:4/24/2008

NEW YORK (April 24, 2008) -- The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).

While all lymphoma types can be cured or managed as a chronic disease, its complexity and variation do not allow for a one-size-fits-all treatment approach. Instead, it necessitates highly specialized and individualized approaches.

With a dozen new therapies in development -- one of the largest portfolios of lymphoma drugs under development anywhere -- the Herbert Irving Comprehensive Cancer Center of NewYork-Presbyterian Hospital and Columbia University Medical Center is meeting this challenge with highly effective new treatments for the disease, giving hope to the more than one million lymphoma patients worldwide.

In 2006, NewYork-Presbyterian/Columbia recruited Dr. Owen A. O'Connor, one of the world's top lymphoma researchers, to lead its Lymphoid Development and Malignancy Program, and direct more than 25 full-time scientists and physician scientists.

"By increasing the number and quality of treatment options for lymphoma patients, we are improving their chances for survival. This is especially critical for patients who haven't responded to standard therapies," says Dr. O'Connor, who is also chief of the Lymphoma Service at NewYork-Presbyterian/Columbia and associate professor of medicine at Columbia University College of Physicians and Surgeons.

One of the most promising new therapies developed at NewYork-Presbyterian/Columbia is PDX (pralatrexate) for T-cell lymphoma -- among the most fatal forms of the disease. The drug is uniquely designed to camouflage itself as a folic acid, which allows it to be absorbed by the tumor, where it attacks the cancer. The therapy has been shown effective in 54 percent of patients who did not respond to other treatments. The drug is now being evaluated around the world, and if its activity is confirmed, it may get regulatory approval some time next year.

"Our hope is that the national multi-center clinical trial that is currently underway to evaluate this drug will result in an improved treatment option for patients," says Dr. O'Connor, who has played a leading role in developing the drug.

Researchers are also exploring novel lymphoma treatments that are not chemotherapies. These include drugs targeting Bcl-6, a gene cloned by Dr. Riccardo Dalla-Favera in 1993, and an enzyme known as histone deacetylase. Work by Dr. Dalla-Favera has shown that drugs affecting these two targets will markedly synergize with conventional chemotherapy, and may lower the amount of chemotherapy necessary to achieve remission.

"We are very excited about the promise of these new therapies. Our lymphoma program includes some of the nation's brightest scientists working together to translate laboratory discoveries into improved treatment options for patients," says Dr. Dalla-Favera, who is director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, director of the Institute of Cancer Genetics at Columbia University Medical Center and Uris Professor of Pathology and Genetics & Development at Columbia University College of Physicians and Surgeons.


'/>"/>

Contact: Jennifer Homa
jeh9057@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
3. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
4. January 1 Looms Large for Lymphoma Patients
5. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
6. Possible Cure for Rare Lymphoma Reported
7. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
8. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
9. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
10. Lymphoma drug used to treat skin disorders
11. Firefly genes allow testing of new therapy against lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... 2017 , ... An intensive search of the medical literature has revealed no ... PhD. He says investigating this possibility, is important because Miami-Dade in 2016 ... infections with HIV. , His findings appear on Analizir.com. . Dr. ...
(Date:3/22/2017)... Providence, RI (PRWEB) , ... March 22, 2017 ... ... Dr. Gwynne Bragdon to its Department of Orthopedic Surgery, Division of Hand, Upper ... extremity and orthopedic surgery. She is board-certified in both Orthopedics and Hand ...
(Date:3/22/2017)... Milford, PA (PRWEB) , ... March 22, 2017 , ... ... producers, according to a US Department of Agriculture report. While excess dairy can ... sensitivity play a role. Lactose sensitivity is the inability to properly digest lactose, a ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... communities throughout north Jersey and the New York metropolitan region, is embarking on ... support for homeless families. , At present, more than two and a half ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a ... greater Nassau County region, is embarking on a combined charity effort with the Great ... For the last 25 years, the Great Neck Breast Cancer Coalition has worked to ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017   Upsher-Smith Laboratories, Inc . (Upsher-Smith) today announced ... 50 mg and 75 mg, the generic equivalent to Mallinckrodt ... The clomipramine hydrochloride capsules market had U.S. sales of ... according to IMS Health. ... "Upsher-Smith has long been recognized within the ...
(Date:3/22/2017)... , March 22, 2017  As the world,s leading ... Lymphoma Society (LLS) has played a role in most ... of which are even helping patients with other cancers ... LLS,s significant investment in cutting-edge research – more than ... to grow with the record-breaking sum of $4.1 million ...
(Date:3/22/2017)... N.C. , March 22, 2017  Levine ... computed tomography (CT) unit designed to address lung ... populations across the Carolinas. The mobile lung unit ... lung cancer education and treatment interventions through integrated ... Financial barriers and a lack ...
Breaking Medicine Technology: